Key facts
- ElmediX’s last known valuation is $39.8M (Jul 2025).
- It has raised $14.4M; the latest was Later Stage VC ($2.3M) in Jul 2025.
- Notable investors include Algimo, Next Invest, University of Antwerp, VLAIO.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for ElmediX
- ·The full record, as it builds
Funding rounds
No funding rounds for ElmediX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ElmediX
Developer of a thermal therapy designed to offer an improved treatment with reduced side effects. The company's therapy is a treatment that strengthens the immune system, kills cancer cells, increases the absorption of chemotherapy drugs, and makes cancer cells more sensitive to radiation, enabling healthcare industry to develop products that have a minimal impact on the environment in terms of design, raw materials, production, packaging, recycling, and waste disposal.
- Sector
- Healthcare
- HQ
- Mechelen, Belgium
- Founded
- 2015
- Employees
- 16
- Website
- elmedix.com/
- Ownership
- Privately Held (backing)
ElmediX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ElmediX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ElmediX in its N-PORT filings yet. We sweep new filings monthly.